Abstract
An orally active vaccine capable of boosting SARS-CoV-2 immune responses in previously infected or vaccinated individuals would help efforts to achieve and sustain herd immunity. Unlike mRNA-loaded lipid nanoparticles and recombinant replication-defective adenoviruses, replicating vesicular stomatitis viruses with SARS-CoV-2 spike glycoproteins (VSV-SARS2) were poorly immunogenic after intramuscular administration in clinical trials. Here, by G protein trans-complementation, we generated VSV-SARS2(+G) virions with expanded target cell tropism. Compared to parental VSV-SARS2, G-supplemented viruses were orally active in virus-naive and vaccine-primed cynomolgus macaques, powerfully boosting SARS-CoV-2 neutralizing antibody titers. Clinical testing of this oral VSV-SARS2(+G) vaccine is planned.
Keywords: Neutralizing antibodies; Oral vaccine; Rhabdovirus; SARS-CoV-2; T cells; VSV.
【저자키워드】 SARS-CoV-2, Neutralizing antibodies, T cells, Oral vaccine, Rhabdovirus, VSV., 【초록키워드】 Vaccine, immune response, Immunity, clinical trials, virus, VSV, SARS-CoV-2 spike glycoprotein, clinical, cell tropism, oral, SARS-CoV-2 neutralizing antibody, cynomolgus macaques, intramuscular, Lipid nanoparticle, administration, G protein, help, effort, virion, stomatitis, vaccinated individual, parental, poorly immunogenic, 【제목키워드】 Vaccine, SARS-CoV-2 immunity,